Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine.
40+
Patient organizations

contributed to its development.

77 000+
Novartis employees¹

own it as an aspiration to embed the perspective of patients and caregivers systematically in our decision-making.

Novartis Commitment to Patients and Caregivers | Novartis

Four pillars of our Commitment

Agreement icon

Respecting and understanding the patient community perspective

Planet icon

Expanding access to our medicines

Doctor icon

Conducting responsible clinical trials

Search icon

Recognizing the importance of transparency and reporting

We recognize the importance of patients and caregivers understanding what they can expect from Novartis.

To date, we have delivered on the following commitments

94%
of early research programs

in general medicines were developed with patient perspective and insights before first-in-human trials (healthy volunteers).

7 194
new patients were reached through managed access programs (MAPs)²

with 94% of requests approved for 37 compounds in 62 countries.

81
clinical development projects³

with 46 diseases comprising 83 clinical trials, had a patient engagement component to obtain their perspective on the design and/or conduct of clinical trials.

191
clinical trials

with Patient Reported Outcomes (PROs) were conducted in 81 countries.

30m
patients reached⁴

through access approaches.

  1. 2025 data
  2. https://www.novartis.com/healthcare-professionals/managed-access-programs.
  3. https://www.novctrd.com/#/terms.
  4. Includes patients reached with medicines through Novartis Global Health, as well as patients reached with support programs, emerging market brands and donations.